In drug discovery, the potential of cytochrome P450 inhibition of new chemical entities is frequently quantified in terms of IC 50 values. In early drug discovery, a risk classification into low, medium, or high potential inhibitors is often sufficient for ranking and prioritizing of compounds. Although often 6 or more inhibitor concentrations are used to determine the IC 50 value, the question arises whether it is possible to predict the risk class based on fewer inhibitor concentrations with comparable reliability. In this article, the authors propose a new integrated 2-point method with inhibitor concentrations chosen in accordance with the risk classification. They analyze its predictive power and the feasibility of not only classifying the compounds into different risk classes but also ranking those compounds that have been binned into the middle risk class. The proposed integrated 2-point method is thus highly suitable for automation. Altogether, it maintains the quality of the prediction while considerably reducing time and cost. The proposed method is applicable to other IC 50 assays and risk classifications. (Journal of Biomolecular Screening 2007:92-99) 
INTRODUCTION
C YTOCHROME P450 (CYP)-MEDIATED METABOLISM accounts for the main pathway of drug elimination from the body for the 200 best-selling drugs. 1 Inhibition of these metabolic enzymes by a coadministered second drug can lead to a substantial increase of the parent drug concentration. 2 This effect is commonly known as CYP-mediated drug-drug interaction and may give rise to severe side effects up to the necessity of a drug withdrawal from the market. 3 Therefore, along with determination of target potency and selectivity of a new chemical entity (NCE), it is common practice in drug discovery to screen for the CYP inhibitory potential, applying various types of assays. 4 In early project phases, it may be sufficient to qualitatively guide the progress of the project by the so-called Crespi assay, 5 a flowchart of which is depicted in Figure 1 . In a broad sense, the obtained IC 50 values are used for ranking purposes within 1 compound series and binned into classes exhibiting a high (IC 50 < 1 µM), a moderate (1 µM < IC 50 < 10 µM), and a low (IC 50 > 10 µM) potential for drug-drug interaction (DDI). In later project phases, more time-and cost-intensive assays are used to characterize the compounds of interest more accurately. 6 To keep pace with the dynamics of drug discovery and further economize these routinely used in vitro assays, mathematical methods were exploited to predict IC 50 values with as few as possible inhibitor concentrations while maintaining a high correlation to the reference IC 50 assay with 6 inhibitor concentrations. As has been reported in other studies, 7, 8 the predictive power of methods based on 1 or 2 inhibitor concentrations varies with the chosen concentrations and suffers from increasing variability at IC 50 values far away from the chosen inhibitor concentrations. To fix this drawback, either the statistical model is changed, as in Ueng et al., 7 or different (a priori unknown) inhibitor concentrations are chosen for different compounds, as in Venkatakrishnan et al. 8 Neither solution seems satisfactory from a theoretical or practical point of view. The present study focuses on the problem of how to reliably predict the risk classes, in some sense a coarsegrained IC 50 value, with as few as possible inhibitor concentrations and how to optimally choose the concentrations to obtain the most reliable predictions. Applying the herein proposed approach, we obtain a high predictive quality (90% correctly predicted). Furthermore, the variability at the most critical regions is minimized by choosing inhibitor concentrations at the boundary of the risk classes (1 µM and 10 µM for the chosen risk classification depicted in Fig. 1 ) and thereby avoiding the above-mentioned drawbacks. The presented approach can easily be adapted to various assay types and different risk classifications. Table 1 . Fluorogenic substrates of the various isoenzymes were 3-cyano-7-ethoxycoumarin (CEC) for CYP1A2 and 2C19, 7-methoxy-4-trifluoromethylcoumarin (7-MFC) for CYP2C9, 3-[2-(NN-diethyl-N-methylamino)-ethyl]-7-methoxy-4-methylcoumarin (AMMC) for CYP2D6, and 7-benzyloxy-trifluoromethylcoumarin (7-BFC) for CYP3A4. Potassium phosphate buffer at pH 7.4 was used as incubation media; cofactors consisted of glucose-6-phosphate (G6P), NADP+, MgCl 2 , and G6P-dehydrogenase (G6PD); and acetonitrile/Tris base at 0.5 M (80/20, [v/v]) served as stop reagent.
MATERIALS AND METHODS

Materials
CYP inhibition Crespi assay
The assay was carried out according to the protocol published by Crespi and Stresser. 6 Incubations were performed by using a Heidolph Titramax 1000 incubator (Heidolph Instruments, Schwabach, Germany) at 37 °C and 750 rpm for 15 to 45 min (see Table 1 ). A Fluostar ® Galaxy plate reader (BMG-Labtechnologies, Offenburg, Germany) was used for fluorometric data generation. Concentrations of the various components are listed in Table 1 . Test compounds were dissolved in acetonitrile to a stock solution at 3 mM, yielding a final solvent concentration of 2% in the assay. The compounds were investigated with regard to their DDI potential for the CYP isoenzymes 1A2, 2C9, 2C19, 2D6, and 3A4. IC 50 determinations were based on 6 concentrations at 0.12, 0.37, 1.1, 3.3, 10, and 30 µM and were performed at least in duplicate. Only compounds with an IC 50 less than 30 µM were taken as a basis for the study because this group of compounds is the more critical and challenging one. For compounds showing inconsistent data, the IC 50 has been corrected by excluding misleading data points from the calculation. Compounds exhibiting autofluorescence were excluded from the data evaluation because, for these compounds, an IC 50 determination cannot be reliably performed using the Crespi assay.
Dose-response models
The commonly used model to determine the IC 50 of an NCE from given in vitro data is to fit the sigmoid dose response,
derived from the Hill equation [8] [9] [10] to the experimental data, where x denotes the inhibitor concentration, max the maximal percent inhibition, and min the minimal percent inhibition of the enzyme. Often, min and max are set to 0% and 100%, respectively, and we adopt this practice here. Moreover, h denotes the Hill coefficient that determines the slope of the sigmoidal curve and reflects the extent of cooperativity. 7 The IC 50 value and the Hill coefficient are determined by solving a nonlinear least squares problem 11 to minimize the differences between the model and the experimental inhibition data.
A different number of experimental data (inhibitor concentrations) can be used as a basis for fitting the sigmoid doseresponse model. In broad terms, the more data are used for the fit, the more accurately the IC 50 can be determined because outliers and variability in the experimental conditions will be averaged out. However, particularly in the early stages of drug discovery, a rough determination of the CYP inhibition potential of an NCE without many (costly) measurements is desired for ranking and prioritization purposes within 1 program.
For our study, the reference scheme for determining the risk class is based on the 6-point IC 50 (i.e., fit of the sigmoid doseresponse model to the 6 data points ranging from 0.12 to 30 µM). This method is taken as a reference to evaluate the predictive power of the integrated 2-point method (i.e., fit of the sigmoid dose-response model), (2) to 2 data points at 1.1 and 10 µM (chosen in accordance with the risk classification), with a variable Hill coefficient or with h = 1. Gao et al. 9 suggested the use of a 1-point method. In this case, the IC 50 can be determined explicitly by solving for IC 50 :
under the additional assumption that the Hill coefficient is fixed to 1. In our analysis, the 1-point method at 1.1 µM, 3.3 µM, or 10 µM is included.
RESULTS
In the following subsections, the different methods are studied with respect to their ability to classify a compound into the One-point method at 1.1µ µM, 3.3 µ µM, or 10 µ µM
The 1-point method at 1.1 µM, 3.3 µM, or 10 µM allows one to obtain good predictions for compounds with an IC 50 close to the corresponding inhibitor concentration at 1.1 µM, 3.3 µM, or 10 µM, respectively (see Fig. 2 and Fig. 3, left) . However, the larger the difference between the 6-point IC 50 and the chosen inhibitor concentration for the 1-point method, the larger are the variations of the predicted IC 50 values. In other words, the 1-point method at 1.1 µM focuses on the range of IC 50 values around 1.1 µM, whereas the 1-point method at 10 µM focuses on the range of IC 50 values around 10 µM (and analogous for 3.3 µM). In addition, due to the usage of just a single measurement, even negative IC 50 values are predicted from equation (3): there are 8 negative IC 50 values predicted by the 1-point method at 1.1 µM, 6 negative predictions by the 1-point method at 10 µM, and 0 negative predictions by the 1-point method at 3.3 µM (points not shown in Figs. 2, 3) .
One possibility of fixing the disadvantage of either 1-point method is to combine 2 IC 50 values in a weighted sum. Denote by IC 50,x the IC 50 value at x = 1.1 µM or x = 10 µM. Then we define the weighted sum by (4) with w x = |(percent inhibition at x µM) -50)|. The above weighting scheme between the 2 IC 50 values is designed in such a way that the inhibitor concentration with percent inhibition closer to 50% inhibition has more control of the overall IC 50 value. As a result, the predictive power increases (see Fig. 3 , right). However, still there is the possibility of predicting negative IC 50 values (2 negative predictions).
Another strategy to fix the disadvantage of the 1-point methods could be to choose out of 2 IC 50 values the one whose IC 50 value is closest to its underlying inhibitor concentration. The results are comparable to the method based on the above weighting scheme (data not shown).
Integrated 2-point method at 1.1 µ µM and 10 µ µM
Instead of combining two 1-point IC 50 values, the integrated 2-point method directly fits the sigmoid dose-response model to 2 data points. The IC 50 values resulting from the integrated 2-point method are shown in Figure 4 for the variable Hill coefficient (left) and fixed Hill coefficient, h = 1 (right), as in the case of the 1-point methods. Although the 1-point methods at most allow one to classify the compounds into the 3 different risk classes, the integrated 2-point methods not only have a higher reliability to be classified into the 3 risk classes but also offer the possibility to rank compounds in the middle risk class. To quantify the correlation between the IC 50 value of the 6-point and the integrated 2-point method, Pearson correlation coefficients were computed based on all 290 compounds and based solely on those compounds that have been ranked into the middle risk class (by the integrated 2-point method). As can be inferred from Table 2 , the overall correlation is less than 89% (for both methods), whereas the correlation in the middle risk class is as high as 95%.
Comparison of the different methods
In risk classes, the number of data points in each risk class, and the Pearson correlation coefficients based on all 290 compounds and based only on those compounds that have been ranked into the middle risk class are reported. As a result, the integrated 2-point method turns out to be the most reliable method.
DISCUSSION
Streamlining in vitro assays to make them more cost-effective is of high importance when dealing with an increasing number of compounds in terms of growing time, capacity, and budget restraints. However, streamlining is only cost-effective if it does not come at the cost of losing predictive power or accuracy (i.e., if it maintains the value of the assay for decision making). We have therefore analyzed mathematically how the 6-point CYP inhibition IC 50 assay can be slimmed down without compromising its predictive power and hence its use for drug discovery.
Our analysis of the 1-point method 9 at 1.1 µM, 3.3 µM, and 10 µM clearly reveals some serious limitations. The 1-point method has its predictive focus for IC 50 values close to the inhibitor concentration used (1.1 µM, 3.3 µM, or 10 µM, respectively) . The larger the difference of the used inhibitor concentration from the predicted IC 50 value, the larger the dispersion (see Fig. 2 and Fig. 3, left) . Gao et al. 9 analyzed the potential of using a single inhibitor concentration to estimate IC 50 values. Although their model well predicted the (logarithm of the) IC 50 value for a small test set of compounds based on a single inhibitor concentration at 3 µM, they had to modify and increase the complexity of the model to regain a comparable predictive quality when analyzing an additional 396 new compounds: "with the larger set, it was found necessary to either fit a curve or fit a model with several slopes." 9 From our analysis, this effect can easily be explained:
The larger and more diverse the set of compounds, the more diverse the range of IC 50 values. As a consequence, the variability at values distant from the chosen inhibitor concentration increases, thereby decreasing the quality of the 1-point method. In addition, the theoretical justification of their analysis is arguable becausebased on the relation in equation (1)-one would not expect a linear relation between the percent inhibition at x and the log(IC 50 ) value, as done in Gao et al. 9 Rather, one would expect a hyperbolic relation, which can nicely be seen in Figure 4 of Gao et al. 9 The insight in the 1-point methods motivated the use of 2-point methods. Moody et al. 10 also analyzed the predictive power of a 2-point IC 50 method. They found a high correlation between IC 50 values computed by a 7-point method versus their 2-point method. However, they used different inhibitor concentrations for their 2-point method, depending on the IC 50 value predicted by the 7-point method: 0.5 and 5 µM were used for inhibitors with IC 50 lower than 0.5 µM, 5 and 50 µM were used for inhibitors with IC 50 between 0.5 and 250 µM, and 50 and 500 µM were used for inhibitors with IC 50 greater than 250 µM. 10 This way, they obtained a good correlation between their 2-point IC 50 and the 7-point IC 50 . However, by this method, a pre-IC 50 determination needs to be done, which would not significantly decrease the time and costs invested.
Trying to overcome this practical limitation, we advise a new integrated 2-point method based on inhibitor concentrations chosen at the boundaries of the risk classes-in our case, 1.1 and 10 µM. This way, we force the method to be as accurate as possible around the set risk boundaries. This results in a highly reliable classification into the 3 categories. The performance can be seen in Figure 4 : Although the dispersion is moderate at 1.1 and 10 µM, it increases at either end, where, however, it does not have any influence on the risk class. In addition, the high correlation coefficient of the middle category permits one to rank the compounds according to their IC 50 value between 1 and 10 µM. This has important implications for real-life project support. For projects with a high scatter of IC 50 values, binning may be of sufficient help to identify promising compounds. However, if many compounds fall into the middle category, simple binning would be of no help to guide chemical optimization. Because the integrated 2point method maintains the ranking power of the 6-point method, it can fully be replaced without losing resolution for structurebased support of medicinal chemistry and rational guidance of lead optimization.
When comparing the 1-point/2-point methods to the reference 6-point method, there are at least 2 possible explanations for deviations between either 2 methods: (1) when analyzing 6 points, it is obviously easier to spot experimental outliers or autofluorescence of a compound than by looking at just 1 or 2 points. Thus, with fewer inhibitor concentrations used for the calculation, we lose the possibility of a posteriori correcting the experimental data based on visual inspection. (2) It is easier to cope with variability when analyzing 6 data points in contrast to just 1 or 2 because errors will average out in the former case. As the analysis demonstrates, the predictive power of the proposed integrated 2-point method is 90%, suggesting that by using this approach, 2 measurements contain enough information for predicting a risk class of an NCE even without the possibility of excluding misleading data points from the analysis as in the 6-point method. In pharmaceutical practice, the performance will be even higher compared to our analysis because only compounds with an IC 50 less than 30 µM were taken as a basis for the study, and NCEs showing very weak or no potential for CYP inhibition are determined easily.
The integrated 2-point method is directly linked to the classification of the inhibitory potential into the 3 risk classes: high (IC 50 ≤ 1 µM), medium (1 µM < IC 50 < 10 µM), and low (IC 50 ≥ 10µM). In principle, the approach can easily be adapted to a different classification scheme. However, if the distance between the boundary concentrations chosen becomes too large (e.g., 2 orders of magnitude), the dispersion is likely to be increasing between these points, thereby compromising the resolution within this class.
CONCLUSION
In this article, we show that the proposed integrated 2-point method allows reducing the number of concentrations from 6 to 2 while maintaining the resolution of the assay, both in terms of binning compounds into 3 risk classes and in reliably ranking compounds binned into the middle class.
The predictive power of the proposed integrated 2-point method is 90% compared to the reference 6-point IC 50 method, which is well within the experimental error of the method. The method is attractive for automated assays, which often run with few concentrations, and may allow one to fully abandon the 6point method from screening.
In conclusion, a validated, rapid, and cost-effective ranking and prioritization tool to estimate the drug-drug interaction potential for NCEs at an early stage of the drug discovery process is presented herein. The approach can easily be adapted to different assay protocols or borders of risk classification.
